Laurus Labs FY21 Annual Report Takeaways 🔬
'Capex plans are already under way to increase capacity by 1.8x by 2022'
Hit the 'retweet' & help us educate more investors.
A Thread 🧵👇
1/ About the company:
Leadership position in generic APIs with a major focus on Antiretroviral drugs, Hepatitis C & Oncology drugs
FDF: Moved up the value chain in formulations
Synthesis (CDMO): KSMs, Intermediates & APIs to pharma innovators.
Bio: Recombinant products
2/ Strengths of the business:
Robust R&D & Process chemistry skills
Compliance that meets the most stringent regulatory expectations (USFDA, etc)
Long-standing relationships | Top 10 global pharma cos. catered
750+ scientists (R&D) | 61 DMFs | 27 ANDAs | 150 patents (292 filed)
3/ APIs: 54% of rev
- Leaders in various high-value & high-volume APIs.
- 4 high potent manufacturing facilities: 4186 KL, increasing capacity by 24% (Strong demand)
- ARV APIs were up 70% | Onco APIs up 25% | Other APIs up 56% (higher contract manufacturing orders from 🇪🇺)
4/ Formulations: 35% of rev
- Backwardly integrated: in house APIs
- Sales to LMIC, 🇺🇸 & 🇪🇺
- 27 ANDA filled: 9 approved+ 8 tentative.
- Capacity of 5 Billion units/yr, Increasing capacity by 100%
- Sales up 102% (growth across markets)
- Launched TLE 400 in the LMIC market